1 **TITLE PAGE:** 2 3 Health Economics Assessment of Statin Therapy Initiation Thresholds for 4 Atherosclerosis Prevention in China: a Cost-Effectiveness Analysis 5 6 **Authors:** Tianyu Feng<sup>a</sup>, Xiaolin Zhang<sup>a</sup>, Jiaying Xu<sup>a</sup>, Shang Gao<sup>a</sup>, Xihe Yu<sup>a</sup> 7 8 **Affiliations:** 9 10 <sup>a</sup> School of Public Health, Jilin University, Changchun, China; 11 12 \*Corresponding Author: 13 Xihe Yu, Ph.D 14 Professor 15 School of Public Health 16 Jilin University 17 Changchun City, Jilin Province, China, 130021 18 Tel: 0431-85619446 19 E-mail: xhyu@jlu.edu.cn 20

41

45

47

Abstract 22 Background: The latest revised Chinese guidelines for the management of 23 dyslipidemia have lowered the 10-year risk threshold for initiating statins for primary 24 prevention of atherosclerotic heart disease. The aim of this study was to examine the 25 negative impact of different statin treatment initiation thresholds on diabetes in a 26 Chinese population and to assess their health economics value. 27 **Methods:** In this study, we constructed an event probability-based Microsimulation 28 model to assess the health economics value of statin therapy. The model was based on 29 the Prediction for atherosclerotic cardio-vascular disease (ASCVD) risk in China 30 (China-PAR) and used data from a nationally representative survey and published 31 meta-analysis of the Chinese middle-aged and elderly population as input. We 32 evaluated four different strategies: a 7.5% 10-year risk threshold strategy, a guideline 33 strategy, a 15% 10-year risk threshold strategy, and a 20% 10-year risk threshold 34 strategy. Additionally, we calculated the incremental cost per quality-adjusted life year 35 (QALY) obtained for each strategy to better understand the economics of the various 36 strategies. 37 **Result:** The incremental cost per QALY for the 10% 10-year risk threshold strategy, 38 compared to the untreated, was \$52,218.75. The incremental cost per QALY for the 39 guideline strategy, compared to the 7.5% 10-year risk threshold strategy, was 40 \$464,614.36. These results were robust in most sensitivity analyses. Conclusion: The current 10-year ASCVD risk thresholds used in China's 42 dyslipidemia management guidelines are cost-effective in preventing ASCVD events 43 and should be maintained with the current statin initiation thresholds. Relaxing the 44 initiation threshold as willingness to pay increases would be more cost-effective. 46 **Keyword:** Statins; Cost-effectiveness analysis; CHARLS; Risk threshold

# Introduction

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

The disease spectrum in China has undergone significant changes in the last three decades. Cardiovascular diseases have replaced infectious diseases as the leading cause of death[1]. According to statistics, more than 40% of deaths in China are due to cardiovascular diseases, with dyslipidemia being an important risk factor for atherosclerotic cardiovascular disease (ASCVD)[2, 3]. To reduce the risk of major cardiovascular adverse events, clinical guidelines from various countries have recommended the use of statins to manage dyslipidemia[4-6]. A mixture of risk factor rules and absolute risk rules are used in the vast majority of guidelines to determine the conditions that trigger statin intervention, but the threshold for statin initiation recommended in different guidelines varies widely. For example, in the 2016 guidelines in China, statins are recommended for primary prevention when a patient has a 10-year ASCVD risk of 10%[4], whereas in Scotland, intervention is triggered when a patient has a 10-year ASCVD risk of 20%[7]. Some countries have set this standard even lower, such as the American Heart Association in its 2018 guideline on blood cholesterol management and the National Institute for Health and Clinical Excellence (NICE) in the UK in the latest version of its revised guideline in 2023, which sets a 10-year incidence of ASCVD of 7.5% as the threshold for triggering statin intervention[5, 6]. An Australian study concluded that a 10-year risk threshold of 15% is more cost-effective than a risk threshold of 5% or 10% for patients with coronary heart disease (CHD) and stroke[8]. It is important to consider the economic value when developing intervention initiation thresholds, especially in developing countries such as China. Chinese guidelines for dyslipidemia management recommend initiating statin therapy when a patient's 10-year risk of ASCVD exceeds 10%. However, this threshold remains a subject of debate within the academic community[4, 9]. Economic considerations must be taken into account when setting the threshold. A threshold that

is too low may result in increased treatment costs for less vulnerable subgroups without a corresponding increase in health benefits. Conversely, a threshold that is too high may result in undertreatment of patients who could benefit from statins. Although statins effectively control dyslipidemia, they also increase the user's risk of developing diabetes, which significantly affects the occurrence of ASCVD[10-12]. With the highest burden of diabetes in the world[13], China needs to investigate the effect of different statin initiation thresholds on diabetes risk and analyze the cost-effectiveness of statins in preventing ASCVD. This study aims to provide valuable reference information for clinicians and policymakers to develop rational, effective, safe, and economically feasible dyslipidemia management programs. Each country must conduct a cost-effectiveness analysis to determine the optimal threshold for initiating treatment based on its population profile, healthcare level, and economic level.

Methods

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

**Model Structure** This study developed a microsimulation model to simulate lifetime ASCVD-related outcomes and costs for individuals aged 40-89 years[14]. The model is based on a modified Markov state model, where individuals transition between health states based on transfer probabilities. Upon entering the model, each individual is assigned parameters such as age, sex, physiological indicators, disease history, and treatment status based on demographic distribution parameters obtained from the 2015 China Health and Retirement Longitudinal Study (CHARLS). The upper age limit of individuals in the model is 89 years old due to the small proportion of the Chinese population aged 90 and above [15]. Individual physiological parameters are updated according to a regression equation as a function of age, as described in Table S5 of the Supplementary Material. The probabilities of lethal and nonlethal cardiovascular and stroke events for individuals in the model were calculated from the risk function constructed by China-PAR (Supplementary material Table S6) [9, 16]. The risk of ASCVD is recalculated for individuals in each cycle based on their current physiological parameters, medical history, and treatment status. In the model, individuals are also affected by background mortality. The probability of a diabetic event is based on the annual incidence of diabetes in Chinese adults obtained from previous studies, with the relative risk of statin-induced diabetes calculated and reassigned if the individual is taking statins. Individuals who discontinue treatment will have their baseline incidence rate restored in the next cycle. The model runs on a one-year cycle, with cost and health utility values updated at the end of each cycle. If an individual does not die or reach the modeled age of simulation

termination, the simulation proceeds to the next cycle. If an individual dies or reaches

the age of simulation termination, the simulation stops and costs, health benefits, and occurrences of events are recorded throughout the simulation period. The model structure is shown in Figure 1 and was implemented using Treeage Pro2019 software.




Figure 1. Structure of the microsimulation model. CHD events include all fatal coronary events and non-fatal AMI.

#### Risk of ASCVD events

118

119

120

121122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

This study used a total risk equation derived from China-PAR to assess the 10-year composite risk of ASCVD events[9, 16]. The 2016 revised Chinese guidelines for the prevention and treatment of dyslipidemia in adults and the Chinese guidelines for cardiovascular disease prevention both recommend using China-PAR as an ASCVD risk assessment tool[4]. The China-PAR risk assessment tool has been widely used in clinical care in China and has been shown to be reliable and valid. China-PAR predicts fatal CHD events (all events caused by acute myocardial infarction (AMI) or other fatal events caused by coronary death), non-fatal AMI, and the 10-year composite probability of fatal and non-fatal stroke. The 10-year probability was converted to a 1-year probability using the DEALE method[17]. The 10-year composite probability of fatal AMI included the 10-year probability of CHD (29.46%) and stroke (70.54%), using their respective proportions of total CHD and stroke events[18]. Patients who survived a CHD event or stroke and did not have a recurrent CHD or stroke event had more than twice the background mortality rate at all follow-up cycles[19]. In the model, individuals who never experienced any ASCVD event were likely to die from background mortality (Supplementary material Tables

142 S2). 143 144 **Simulation population** 145 At the beginning of the simulation, the model consisted of 10,000 individuals without 146 a history of ASCVD. Parameters for ASCVD-related risk factors were obtained from 147 the 2015 CHARLS, and all other model inputs are shown in the Supplementary 148 Material (Supplementary material Tables S1, S3 and S4)[20]. To model changes in 149 ASCVD risk factors (mainly HDL-C, TC, SBP, and WC) over time, cross-sectional 150 linear regression was performed using CHARLS data to obtain the relationship 151 between ASCVD risk factors and age (Supplementary material Tables S5) in the 152 China-PAR risk function[17]. Data on the prevalence of diabetes and the increased 153 risk of developing diabetes due to statins at each age were obtained from studies in 154 the literature[21]. 155 156 **Treatment Strategies** 157 The guideline treatment-initiation strategy is illustrated in electronic supplementary 158 material Fig. S1. This study discusses statin treatment regimens based on the 2023 159 edition of the Chinese guidelines for lipid management, focusing on the 10-year 160 ASCVD composite risk threshold in the guidelines. The China-PAR risk equation was 161 used to determine patients' 10-year risk of combined ASCVD onset[22]. The 162 guidelines recommend the use of moderate-intensity statins as primary prevention. 163 High-intensity statin therapy was not analyzed because the guidelines suggest that it 164 should be used with caution in the Chinese population[4]. Based on previous studies, 165 it was assumed that 40% of patients would discontinue treatment on their own after 166 one year, and that all patients should adhere to long-term statin treatment [23, 24]. 167 168 Since diabetes significantly affects the risk of developing combined ASCVD and 169 statins can slightly increase the risk of developing type 2 diabetes[17, 25], this study

focuses on the effect of statin-induced diabetes on the combined risk of ASCVD[26, 27]. It was assumed that patients with statin-induced diabetes had good glycemic control and no other comorbidities. In the simulation model, only the effects of statin-induced diabetes on quality of life and costs were included.

We analyzed 10-year risks of 7.5%, 10%, and 15% to explore optimal treatment initiation thresholds. These simulated regimens were similar to the strategies in the guidelines, with treatment initiation based on the China-PAR risk function. Treatment-free simulations were also performed.

## Cost and health utility

This study uses the perspective of the Chinese health care system, and costs include only direct medical costs associated with ASCVD, such as statin purchase, inpatient, and outpatient costs (Table 1). Drug costs were obtained based on the 2020 national negotiated prices. We followed the methodology of a similar study and calculated annual drug costs by averaging the lowest winning prices of statins from local government procurement catalogs in each region of China in the first quarter of 2020. Assuming that post-CHD and post-stroke individuals require one outpatient visit per year for the remainder of their lives, we expanded the costs to 2022 using the China Healthcare Component Consumer Price Index.

Parameter	Value	Value Distribution		References
Acute disutility				[28]
Coronary heart disease	0.439	Beta	0.018	
Stroke	0.92	Beta	0.04	
Post-event long-term disutility				[28,29]
Acute myocardial infarction	0.107	Beta	0.019	
Stroke	0.266	Beta	0.02	
Treatment effect on CHD (OR)	0.7	Log-normal	0.072	[22]
Treatment effect on stroke (OR)	0.81	Log-normal	0.069	[22]
Risk of statin-induced diabetes (OR)	1.21	Beta		[30]
Annual statin treatment costs	1,149.75	Gamma		

Costs (2022 CN¥)	AMI	Stroke		
Hospitalization costs	22,611	13,983	Gamma	[31]
First-year long-term costs	5,255.85	2652	Gamma	[32]
Office visit costs in subsequent	E0E 07	565	Commo	[22]
years	585.87	565	Gamma	[33]
CHD mortality by age group	Men	Women		[32]
34-44	0.12	0.18	Beta	
45-54	0.21	0.23	Beta	
55-64	0.29	0.27	Beta	
65-74	0.33	0.43	Beta	
75-84	0.48	0.51	Beta	
Stroke mortality by age group	Men	Women		[32]
34-44	0.25	0.18	Beta	
45-54	0.18	0.14	Beta	
55-64	0.12	0.15	Beta	
65-74	0.2	0.2	Beta	
75-84	0.45	0.45	Beta	

190 Table 1. Parameters used in the model.

QALYs were calculated using age-specific utility weights and event-related negative utility weights, which can be further categorized into acute and long-term negative utility for patients surviving only in the acute phase(Table 1). Age-specific utility weights were derived from the EQ-5D survey of the Chinese general population (Supplementary material Tables S2)[34]. Acute and long-term negative utility weights were extracted from the Global Burden of Disease project and the Chinese EQ-5D survey of patients with chronic diseases[29]. In the baseline case, an annual discount rate of 3% was used[35].

## **Intervention Strategy Comparisons**

This study evaluates strategies using the incremental cost-benefit ratio (ICER). The cost-benefit ratio of each alternative is calculated, and inferior strategies are removed. China's gross domestic product (GDP) per capita in 2022 (CNY85,700) is used as the cost-effectiveness criterion, and three times the GDP (CNY257,100) is used as the minimum criterion to be cost-effective[36]. In addition, this study employs

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226227

cost-acceptability curves to illustrate the probability that each strategy is cost-effective at different levels of willingness-to-pay (WTP). Sensitivity Analysis We performed one-way and probabilistic sensitivity analyses (PSA) on the model parameters to assess the robustness of the results when the parameters were varied. In the univariate sensitivity analysis, we focused on the effects of statin effectiveness, price, and induction of diabetes on the optimal ASCVD treatment threshold. In PSA, we assessed overall model uncertainty through 1000 randomized simulations. **Model Validation** The model used in this study was adapted from an extensively validated Microsimulation model[14, 37], and its internal and external validity were validated based on the model output [38, 39]. Specifically, the internal validity of the model was validated by regression analysis, calculating the expected probabilities of CHD and stroke events for each sex-different age group in the untreated group model against the mean of the simulation results (Supplementary material Figure S2). External validity was verified by comparing simulated ASCVD incidence in the age-sex group (10-year interval) with results from other studies (Supplementary material Table S6)[40].

228 Results 229 Model calibration and validation 230 Fig S2 in supplementary material displays the internal validation results of the model. 231 The coefficient of determination R2 for the linear regression on the mean of the 232 1-year expected probability of CHD and stroke events and the corresponding 233 simulated values for the untreated group is 0.9278, indicating good internal validity. 234 The simulated stroke incidence in Table 2 aligns well with the prospective study 235 results. China's current published life expectancy per capita is 75.4 years, while the 236 untreated model simulates a life expectancy of 74.9 years, demonstrating good 237 external validity. 238 239 240 **Clinical Event Results** 241 An ASCVD threshold of 7.5% or higher was associated with an estimated 48% of 242 adults being eligible for statin therapy. Strategies with higher ASCVD thresholds were 243 linked to fewer cases of statin-induced diabetes but more CVD events. When applied 244 to the 573 million adults aged 40 to 75 years in China, shifting from a 15% to a 10% 245 ASCVD threshold was associated with an estimated 1,088,716 additional CVD events 246 avoided. Shifting from a 10% to a 7.5% ASCVD threshold was associated with an 247 estimated 687,610 additional CVD events avoided. In contrast, the number of 248 statin-induced diabetes cases was small. This result demonstrates the net effect of 249 statins in reducing cardiovascular events. 250 251 **Cost-effectiveness analysis** 252 Table 2 presents the base case results of this study. The ICERs for the 15% risk 253 threshold strategy compared to no treatment were \$43,951.82/QALY. The 15% risk 254 threshold strategy is the expansion advantage strategy and was removed from the 255 analysis. The ICERs for the guideline strategy compared to the untreated were

\$52,218.75/QALY. The ICERs for the 7.5% risk threshold strategy compared to the guideline strategy were \$464,614.36/QALY. Therefore, when using the 3-GDP criterion, the 7.5% risk threshold strategy was optimal among the three strategies. When using the 1-GDP criterion, the 10% risk threshold strategy was optimal among the three strategies.

#### **Sensitivity Analysis**

The acceptability curves for the PSA results are displayed in the Figure 2. When using the 3-GDP cost-effectiveness criterion, the guidance strategy has a 32% probability of being optimal, while the 7.5% risk threshold strategy has a 62% probability. When using the 1-GDP criterion, the guidance strategy and the 7.5% risk threshold strategy have equal cost-effectiveness, both with a 30% probability of being optimal. The cost-acceptability curve suggests that the current guideline strategy is more cost-effective than the 7.5% risk threshold strategy when the WTP is below 1-GDP.




Figure 2. Acceptability curves were generated using probabilistic sensitivity analysis results. The horizontal coordinate of the figure represents willingness to pay, calculated in RMB.

The tornado plot displays the one-way sensitivity analysis results (figure 3). When all

parameters are varied within their range of variability, the degree of variation in ICER remains within an acceptable range around 1-GDP. Changes in statin prices and the risk of statin-induced diabetes have the greatest impact on cost-effectiveness results.




Figure 3. The tornado plot displays the results of the deterministic sensitivity analysis. The price of statins and the risk of statin-induced diabetes had the greatest impact on the results.

ASCVD Risk Threshold, %	Adults Statin Eligible, %	Statin-Induced Diabetes Cases	CVD Events	Mean discounted QALYs	Life Expectancy	Mean discounted costs(CN¥ in 2018)	ICER
No Treatment			0.44	12.17	75.34	49360.91	
15%	39%	0.00695	0.43	12.46	75.63	62236.63	Extended dominance
10%	47%	0.00755	0.43	12.47	75.79	65128.64	52218.75
7.50%	56.00%	0.00745	0.43	12.47	75.81	66866.81	464614.36

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

**Discussion** The primary goal of healthcare systems is to optimize health benefits for the population while minimizing expenditure, particularly in the health economics of preventative therapeutic measures [41]. Statins have been demonstrated to be effective in preventing ASCVD, yet their use has been associated with an increased incidence of diabetes, presenting a challenge for policymakers, healthcare professionals, and patients[42, 43]. Our analysis revealed that using a 7.5% 10-year ASCVD risk as the initiation threshold for statin prevention of ASCVD events was more effective than the current Chinese dyslipidemia management guidelines' recommendation of a 10% 10-year ASCVD risk when 3-GDP was used as the criterion. Sensitivity analysis results indicated that the effects of statin sales price and the risk prevention strategy for statin-induced diabetes were more pronounced. Notably, when the price of statins is reduced by 20%, the ICER for the 7.5% threshold strategy will be less than 2-GDP. Overall, our findings suggest that the optimal treatment threshold varies depending on the cost-effectiveness threshold used. For adults without cardiovascular disease, the decision to initiate statin therapy should be based on evidence-based evidence and patient preference. When a patient's ASCVD risk reaches the initiation threshold, they may have valid personal reasons for declining statin treatment[44]. In China, financial reasons often lead patients to discontinue treatment. For many lower-income patients without well-established health insurance, the cost is prohibitive[45]. Our one-way sensitivity analysis indicated that statin-induced diabetes has a significant impact on simulation outcomes. Therefore, greater attention should be paid to the glycemic profile of patients taking statins and to their long-term normative glucose monitoring. Studies evaluating the economics of statin clinical guidelines in other countries and

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

regions have concluded that the threshold for initiating statin therapy could be further reduced. Pandya et al. assessed the cost-effectiveness of the 2013 ACC/AHA guidelines and alternative risk thresholds for preventing ASCVD events. They determined that the 10-year ASCVD ≥7.5% risk threshold used in the ACC/AHA guidelines was acceptably cost-effective, but that cost-effectiveness would be more pronounced if the 10-year ASCVD risk threshold were further reduced (e.g., to  $\geq 3\%$ or ≥4%)[14]. Linda J et al. analyzed current cardiovascular prevention guidelines in Australia and determined that the greatest cost-effectiveness was achieved by recommending statins for individuals with a five-year ASCVD risk greater than 5% or a 10-year ASCVD risk greater than 10%[8]. These studies suggest that more aggressive statin therapy initiation threshold strategies could be further explored. However, because these studies were primarily based on the demographics, healthcare levels, and economic development of developed countries, their results may not be replicable in developing countries like China. Specific statin initiation thresholds should consider the country's willingness to pay. Past economic studies of statins have not addressed the impact of diabetes, preventing the analysis from fully reflecting the actual outcomes of statins in preventing ASCVD. However, the risk functions used in past studies are not the parameters currently needed on the front line and are more difficult to obtain, causing the analysis results to deviate somewhat from the actual situation and making it challenging to meet the practical needs of grassroots work. As a result, previous studies have struggled to produce results that provide practical guidance. By improving the model structure and correcting the parameters, this study obtained valuable references for practical clinical work. Cobiac et al. used the average cost-effectiveness ratio of each strategy, rather than ICER, to compare different absolute risk threshold strategies[8]. Jiang et al. analyzed the cost-effectiveness of different risk thresholds using a DEM model based on a national survey[46]. Unlike our study, their study did not include the risk of

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

statin-induced diabetes in the model, omitting an important factor for ASCVD prevention. Our study addressed this omission. Based on this study's results, we recommend that China maintain its current statin initiation threshold. Although our findings suggest that relaxing the threshold would provide greater health economic benefits, clinical event results indicate that it would only marginally reduce the number of ASCVD events. ASCVD is a complex disease influenced by many factors and may not be best addressed solely through statins. Additionally, cost-effectiveness results show that a 7.5% 10-year ASCVD risk threshold would be more cost-effective with increased willingness to pay. However, China's current economic level is not yet comparable to developed countries, and the average Chinese patient's willingness to pay is low. Therefore, Chinese health policymakers should consider relaxing the treatment initiation threshold only after further economic improvement. Finally, hastily lowering the prophylaxis initiation threshold may cause a broken window effect, leading to increased use of other drugs such as anticoagulants and further burdening China's healthcare system. Markov model studies tend to have certain limitations. Firstly, Markov cohort models use average probabilities to model individual life courses, making it challenging to obtain more realistic simulation results[47]. In this study, we calculated the absolute ASCVD risk for each individual in the model based on demographic and clinical characteristics from the CHARLS study, allowing treatment decisions to be made based on individual risk. Secondly, a major characteristic of Markov cohort models is their memoryless nature, which also makes it difficult to model the impact of historical events on patient disease outcomes and costs[48]. Microsimulation models can address this by tracking each individual historically and adjusting individual transition probabilities and cost parameters across health states based on historical events.

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

This study inevitably has some unavoidable limitations. Firstly, the ASCVD risk function used in this study can only calculate the 10-year combined ASCVD risk, while the risks of developing AMI and stroke cannot be determined separately and must be simulated using a fixed probability level. Secondly, this study focused on the impact of statin-induced diabetes risk on ASCVD prevention and did not explore the health damage and economic loss due to complications in diabetic patients. This is a limitation of our study. Thirdly, previous studies have suggested that statin adherence significantly impacts ASCVD prevention. Due to the lack of data on long-term statin therapy in China, we used studies from other countries to model the impact of poor adherence, which may not accurately reflect the Chinese reality. Finally, although this study modeled the potential risk of statin-induced diabetes, it did not include all potential benefits and risks, such as reduced risk of advanced/aggressive prostate reduced mortality from in-hospital sepsis, and statin-induced cancer, rhabdomyolysis[49-52]. Previous studies have generally considered statin-induced diabetes to be the most significant negative scenario, so the potential factors not included in the analysis likely had minimal impact on this study[46].

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410411

412

413

414

**Conclusions** When willingness to pay is at 1-GDP, the current 10% 10-year ASCVD risk threshold used in China's dyslipidemia management guidelines is cost-effective in preventing ASCVD events. Therefore, the current statin initiation threshold should be maintained. However, relaxing the 10-year ASCVD risk threshold would be a better strategy as willingness to pay increases. Changes in statin prices and the risk of statin-induced diabetes have a significant impact on cost-effectiveness outcomes. **Abbreviations** AMI: Acute myocardial infarction ASCVD: Atherosclerotic cardiovascular disease CHD: Coronary heart disease CHARLS: China Health and Retirement Longitudinal Study China-PAR: Prediction for Atherosclerotic Cardiovascular Disease Risk in China ICER: Incremental cost-benefit ratio PSA: Probabilistic sensitivity analyses QALY: Quality-adjusted life year WTP: Willingness-to-pay **Declarations** Availability of data and materials The datasets supporting the conclusions are available from the corresponding author (Yu X, xhyu@jlu.edu.cn) on reasonable request. **Funding** No fund was received for this study.

415 **Consent for publication** 416 Not applicable. 417 418 **Author information** 419 **Authors and Affiliations** 420 School of Public Health, Jilin University, Changchun, China 421 Tianyu Feng 422 423 School of Public Health, Jilin University, Changchun, China 424 Xiaolin Zhang 425 426 School of Public Health, Jilin University, Changchun, China 427 Jiaying Xua 428 429 School of Public Health, Jilin University, Changchun, China 430 Shang Gao 431 432 School of Public Health, Jilin University, Changchun, China 433 Xihe Yu 434 435 **Contributions** 436 Tianyu Feng and Xihe Yu design research and draft paper. Data collection and 437 analysis is done by Xiaolin Zhang and Jiaying Xu. Jiaying Xu and Shang Gao revised 438 the article and put forward suggestions. All authors commented on previous versions 439 of the manuscript. All authors read and approved the final manuscript. 440 441 Acknowledgment 442 Not applicable.

Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

451

- 452 **References**
- 453 1. Wang, L., et al., Prevalence and Treatment of Diabetes in China, 2013-2018.
- 454 JAMA, 2021. 326(24): p. 2498-2506.
- 455 2. Zhou, M., et al., Cause-specific mortality for 240 causes in China during
- 456 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study
- 457 2013. Lancet, 2016. 387(10015): p. 251-72.
- 458 3. Yang, G., et al., Rapid health transition in China, 1990-2010: findings from the
- 459 Global Burden of Disease Study 2010. Lancet, 2013. 381(9882): p. 1987-2015.
- 460 4. Joint committee for guideline, r., 2016 Chinese guidelines for the management of
- dyslipidemia in adults. J Geriatr Cardiol, 2018. 15(1): p. 1-29.
- 462 5. Grundy, S.M., et al., 2018
- 463 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
- 464 Guideline on the Management of Blood Cholesterol: A Report of the American
- 465 College of Cardiology/American Heart Association Task Force on Clinical Practice
- 466 Guidelines. Circulation, 2019. 139(25): p. e1082-e1143.
- 467 6. guideline CG181, N.I.C.E., Cardiovascular disease: risk assessment and reduction,
- including lipid modification. Methods. 2023, London.
- 469 7. Network, S.I.G., Risk estimation and the prevention of cardiovascular disease.
- 470 2007: Edinburgh: SIGN.
- 471 8. Cobiac, L.J., et al., Improving the cost-effectiveness of cardiovascular disease
- prevention in Australia: a modelling study. BMC Public Health, 2012. 12: p. 398.
- 473 9. Yang, X.L., et al., Risk stratification of atherosclerotic cardiovascular disease in
- 474 Chinese adults. Chronic Dis Transl Med, 2016. 2(2): p. 102-109.
- 475 10. Casula, M., et al., Statin use and risk of new-onset diabetes: A meta-analysis of
- observational studies. Nutr Metab Cardiovasc Dis, 2017. 27(5): p. 396-406.
- 477 11. Mansi, I.A., et al., Association of Statin Therapy Initiation With Diabetes
- 478 Progression: A Retrospective Matched-Cohort Study. JAMA Intern Med, 2021.
- 479 181(12): p. 1562-1574.

- 480 12. Galicia-Garcia, U., et al., Statin Treatment-Induced Development of Type 2
- 481 Diabetes: From Clinical Evidence to Mechanistic Insights. Int J Mol Sci, 2020.
- 482 21(13).
- 483 13. Li, Y., et al., Prevalence of diabetes recorded in mainland China using 2018
- 484 diagnostic criteria from the American Diabetes Association: national cross sectional
- 485 study. BMJ, 2020. 369: p. m997.
- 486 14. Pandya, A., et al., Cost-effectiveness of 10-Year Risk Thresholds for Initiation of
- 487 Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA, 2015.
- 488 314(2): p. 142-50.
- 489 15. MD, W. Population pyramids of the World from 1950 to 2100—China 2022.
- 490 2022.
- 491 16. Yang, X., et al., Predicting the 10-Year Risks of Atherosclerotic Cardiovascular
- 492 Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk
- 493 in China). Circulation, 2016. 134(19): p. 1430-1440.
- 494 17. Beck, J.R., et al., A convenient approximation of life expectancy (the "DEALE").
- 495 II. Use in medical decision-making. Am J Med, 1982. 73(6): p. 889-97.
- 496 18. Wu, Y., et al., Estimation of 10-year risk of fatal and nonfatal ischemic
- 497 cardiovascular diseases in Chinese adults. Circulation, 2006. 114(21): p. 2217-25.
- 498 19. Greving, J.P., et al., Cost-effectiveness of aspirin treatment in the primary
- 499 prevention of cardiovascular disease events in subgroups based on age, gender, and
- varying cardiovascular risk. Circulation, 2008. 117(22): p. 2875-83.
- 501 20. Yang, Z.J., et al., Prevalence of cardiovascular disease risk factor in the Chinese
- 502 population: the 2007-2008 China National Diabetes and Metabolic Disorders Study.
- 503 Eur Heart J, 2012. 33(2): p. 213-20.
- 504 21. Sattar, N., et al., Statins and risk of incident diabetes: a collaborative
- meta-analysis of randomised statin trials. Lancet, 2010. 375(9716): p. 735-42.
- 506 22. Brugts, J.J., et al., The benefits of statins in people without established
- 507 cardiovascular disease but with cardiovascular risk factors: meta-analysis of

- randomised controlled trials. BMJ, 2009. 338: p. b2376.
- 509 23. Simons, L.A., et al., Discontinuation rates for use of statins are high. BMJ, 2000.
- 510 321(7268): p. 1084.
- 511 24. Simons, L.A., M. Ortiz, and G. Calcino, Persistence with antihypertensive
- 512 medication: Australia-wide experience, 2004-2006. Med J Aust, 2008. 188(4): p.
- 513 224-7.
- 514 25. Poznyak, A., et al., The Diabetes Mellitus-Atherosclerosis Connection: The Role
- of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci, 2020.
- 516 21(5).
- 26. Laakso, M. and J. Kuusisto, Diabetes Secondary to Treatment with Statins. Curr
- 518 Diab Rep, 2017. 17(2): p. 10.
- 519 27. Aiman, U., A. Najmi, and R.A. Khan, Statin induced diabetes and its clinical
- implications. J Pharmacol Pharmacother, 2014. 5(3): p. 181-5.
- 521 28. Organization, W.H., The global burden of disease: 2004 update. 2008: World
- 522 Health Organization.
- 523 29. Tan, Z., et al., Health-related quality of life as measured with EQ-5D among
- 524 populations with and without specific chronic conditions: a population-based survey
- 525 in Shaanxi Province, China. PLoS One, 2013. 8(7): p. e65958.
- 526 30. Thakker, D., et al., Statin use and the risk of developing diabetes: a network
- meta-analysis. Pharmacoepidemiol Drug Saf, 2016. 25(10): p. 1131-1149.
- 528 31. Wang, S., et al., Direct medical costs of hospitalizations for cardiovascular
- 529 diseases in Shanghai, China: trends and projections. Medicine (Baltimore), 2015.
- 530 94(20): p. e837.
- 32. Gu, D., et al., The Cost-Effectiveness of Low-Cost Essential Antihypertensive
- Medicines for Hypertension Control in China: A Modelling Study. PLoS Med, 2015.
- 533 12(8): p. e1001860.
- 33. Zhao, W., et al., Economic burden of obesity-related chronic diseases in Mainland
- 535 China. Obes Rev, 2008. 9 Suppl 1: p. 62-7.

- 536 34. Sun, S., et al., Population health status in China: EQ-5D results, by age, sex and
- socio-economic status, from the National Health Services Survey 2008. Qual Life Res,
- 538 2011. 20(3): p. 309-20.
- 539 35. Wang, X., et al., Guideline for postmarketing Chinese medicine
- pharmacoeconomic evaluation. Chin J Integr Med, 2015. 21(6): p. 473-80.
- 36. Robinson, L.A., et al., Understanding and improving the one and three times GDP
- per capita cost-effectiveness thresholds. Health Policy Plan, 2017. 32(1): p. 141-145.
- 543 37. Bleibler, F., et al., Expected lifetime numbers and costs of fractures in
- postmenopausal women with and without osteoporosis in Germany: a discrete event
- simulation model. BMC Health Serv Res, 2014. 14: p. 284.
- 546 38. Eddy, D.M., et al., Model transparency and validation: a report of the
- 547 ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making,
- 548 2012. 32(5): p. 733-43.
- 39. Vemer, P., et al., AdViSHE: A Validation-Assessment Tool of Health-Economic
- Models for Decision Makers and Model Users. Pharmacoeconomics, 2016. 34(4): p.
- 551 349-61.
- 552 40. Wang, W., et al., Prevalence, Incidence, and Mortality of Stroke in China: Results
- from a Nationwide Population-Based Survey of 480 687 Adults. Circulation, 2017.
- 554 135(8): p. 759-771.
- 555 41. Boone, J., Basic versus supplementary health insurance: Access to care and the
- role of cost effectiveness. J Health Econ, 2018. 60: p. 53-74.
- 557 42. Collins, R., et al., Interpretation of the evidence for the efficacy and safety of
- statin therapy. Lancet, 2016. 388(10059): p. 2532-2561.
- 43. Simic, I. and Z. Reiner, Adverse effects of statins myths and reality. Curr Pharm
- 560 Des, 2015. 21(9): p. 1220-6.
- 561 44. Rosenbaum, L., Beyond belief--how people feel about taking medications for
- heart disease. N Engl J Med, 2015. 372(2): p. 183-7.
- 563 45. Xiong, X., et al., Impact of universal medical insurance system on the

- 564 accessibility of medical service supply and affordability of patients in China. PLoS
- 565 One, 2018. 13(3): p. e0193273.
- 46. Jiang, Y. and W. Ni, Economic Evaluation of the 2016 Chinese Guideline and
- 567 Alternative Risk Thresholds of Initiating Statin Therapy for the Management of
- 568 Atherosclerotic Cardiovascular Disease. Pharmacoeconomics, 2019. 37(7): p.
- 569 943-952.
- 570 47. Caro, J.J., J. Moller, and D. Getsios, Discrete event simulation: the preferred
- technique for health economic evaluations? Value Health, 2010. 13(8): p. 1056-60.
- 48. Hiligsmann, M., et al., Development and validation of a Markov microsimulation
- 573 model for the economic evaluation of treatments in osteoporosis. Value Health, 2009.
- 574 12(5): p. 687-96.
- 575 49. Boudreau, D.M., O. Yu, and J. Johnson, Statin use and cancer risk: a
- 576 comprehensive review. Expert Opin Drug Saf, 2010. 9(4): p. 603-21.
- 577 50. Ouellette, D.R., et al., Sepsis outcomes in patients receiving statins prior to
- 578 hospitalization for sepsis: comparison of in-hospital mortality rates between patients
- 579 who received atorvastatin and those who received simvastatin. Ann Intensive Care,
- 580 2015. 5: p. 9.
- 581 51. Mendes, P., P.G. Robles, and S. Mathur, Statin-induced rhabdomyolysis: a
- comprehensive review of case reports. Physiother Can, 2014. 66(2): p. 124-32.
- 583 52. Ganda, O.P., Statin-induced diabetes: incidence, mechanisms, and implications.
- 584 F1000Res, 2016. 5

